Regulatory Open Forum

 View Only
  • 1.  Future of NSIS Italian medical device database?

    Posted 09-Feb-2019 15:08
    ​The NSIS database is an impressive piece of software, though not the most user-friendly. I'm wondering it there are plans to retire it after the new EUDAMED goes live. Or maybe it will be restructured to make use of the shared data?

    ------------------------------
    Anne LeBlanc
    Manager, Regulatory Affairs
    United States
    ------------------------------


  • 2.  RE: Future of NSIS Italian medical device database?

    Posted 10-Feb-2019 04:19
    Anne,

    I am curious too as there are a couple other countries that have some databases as well.  Theoretically once EUDAMED goes live it will contain quite a conglomerate of data including much from NSIS database.  How this will be perceived by individual Member States as being adequate will be another thing ...

    ------------------------------
    Richard Vincins RAC
    Vice President Global Regulatory Affairs
    ------------------------------



  • 3.  RE: Future of NSIS Italian medical device database?

    Posted 11-Feb-2019 04:35
    As far as I understand the situation, one of the Commission's initially stated aims of the MDD 'recast' (remember those days?) was to extend EUDAMED so that there would be no need for local registration databases. However, during negotiations for the MDR, it was clear that most of those countries that had local schemes were unwilling to give them up, so the initially drafted language was dropped. In the case of the Italian scheme, it serves a number of purposes, not just a regulatory one, as it identifies those devices that may be purchased by healthcare facilities working within the government-funded sector, so if your device is not included in the database, it will not, for example, be considered for government tenders or be purchased by national health service facilities. The database also provides a link between the locally-used device nomenclature system (the 'CND' codes, which pre-existed GMDN by several decades) and GMDN codes.

    I'm not sure of the details in the other dozen or so countries that currently require local registration, but my guess is that most, if not all, of these local schemes will remain after MDR full implementation.

    ------------------------------
    Roger Gray
    VP Quality and Regulatory
    Donawa Lifescience Consulting
    Clinical Studies - Regulatory - Quality Systems
    Rome, Italy
    +39 06 578 2665
    rgray@donawa.com
    www.donawa.com
    ------------------------------